Bris­tol-My­ers con­cedes a PhI­II lung can­cer flop for Op­di­vo as com­pe­ti­tion heats up in SCLC

Bris­tol-My­ers Squibb $BMY has run in­to an­oth­er dead end in ex­plor­ing the lung can­cer mar­ket. 

The big biotech re­port­ed that its Phase III study of Op­di­vo failed the Check­Mate-331 study, un­able to beat the stan­dard of care for treat­ing sec­ond-line small cell lung can­cer.

We don’t know yet just what the da­ta are, just that the read­out doesn’t mea­sure up to a win. And the set­back comes just months af­ter Roche’s com­bo us­ing Tecen­triq and chemo won out on first-line cas­es of SCLC, a tough field that ac­counts for about 15% of the over­all lung can­cer mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER